Brief: LogicBio Therapeutics Announces FDA Lifts Clinical Hold On SUNRISE Trial In Pediatric Patients With Methylmalonic Acidemia
09/05/2022 13:39
May 9 (Reuters) - LogicBio Therapeutics Inc LOGC.O :
* LOGICBIO THERAPEUTICS ANNOUNCES FDA LIFTS CLINICAL HOLD ON
SUNRISE TRIAL IN PEDIATRIC PATIENTS WITH METHYLMALONIC ACIDEMIA
* LOGICBIO THERAPEUTICS - IN CONNECTION WITH LIFTING OF
CLINICAL
HOLD, CO AMENDED SUNRISE PROTOCOL IN A MANNER THAT REFLECTED ITS
DIALOGUE WITH FDA
* LOGICBIO THERAPEUTICS INC - EXPECTS TO PROCEED WITH DOSING
AFTER
IT IMPLEMENTS CHANGES TO SUNRISE PROTOCOL
* LOGICBIO-AFTER LIFTING OF CLINICAL HOLD, CO REINSTATING
PREVIOUS
GUIDANCE & EXPECTS TO PRESENT INTERIM CLINICAL DATA FROM SUNRISE
TRIAL BY END OF Q2
Source text for Eikon: ID:nPn4ZrV0ta
Further company coverage: LOGC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ContextLogic Holdings
See all newsContextLogic Holdings Q2 revenue flat as higher prices offset lower volumes
Brief: ContextLogic Holdings Q2 Adjusted EBITDA USD 10.8 Million
ContextLogic Holdings Q1 net income jumps on tax benefit
Brief: ContextLogic Holdings Q1 Net Income USD 17 Million
Brief: Contextlogic To Acquire US Salt From Emerald Lake In $907.5 Million Transaction, Creating New Business Ownership Platform In Partnership With Abrams Capital And BC Partners Credit